Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Ziekten en gezondheid in kaart brengen
Downloaden 1.42 MBAuteurs
Susana Monge [3]; James Humphreys [4]; Nathalie Nicolay [5]; Toon Braeye [6]; Izaak Van Evercooren [7]; Christian Holm Hansen [8]; Hanne-Dorthe Emborg [9]; Sacco, Chiara [10]; Alberto Mateo-Urdiales [11]; Jesús Castilla [12]; Iván Martínez-Baz [13]; Brechje de Gier [14]; Susan Hahné [15]; Hinta Meijerink [16]; Anja Bråthen Kristoffersen [17]; Machado, Ausenda [18]; Patricia Soares [19]; Anthony Nardone [20]; Sabrina Bacci [21]; Kissling, Esther [22]; Baltazar Nunes [23]Trefwoorden
Article written during project(s) :
Samenvatting:
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results ind…